Skip to main content
Erschienen in: Calcified Tissue International 4/2024

14.03.2024 | Original Research

The PDE4 Inhibitors Roflumilast and Rolipram Rescue ADO2 Osteoclast Resorption Dysfunction

verfasst von: Jung Min Hong, Rita L. Gerard-O’Riley, Dena Acton, Imranul Alam, Michael J. Econs, Angela Bruzzaniti

Erschienen in: Calcified Tissue International | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Autosomal Dominant Osteopetrosis type II (ADO2) is a rare bone disease of impaired osteoclastic bone resorption caused by heterozygous missense mutations in the chloride channel 7 (CLCN7). Adenylate cyclase, which catalyzes the formation of cAMP, is critical for lysosomal acidification in osteoclasts. We found reduced cAMP levels in ADO2 osteoclasts compared to wild-type (WT) osteoclasts, leading us to examine whether regulating cAMP would improve ADO2 osteoclast activity. Although forskolin, a known activator of adenylate cyclase and cAMP levels, negatively affected osteoclast number, it led to an overall increase in ADO2 and WT osteoclast resorption activity in vitro. Next, we examined cAMP hydrolysis by the phosphodiesterase 4 (PDE4) proteins in ADO2 versus WT osteoclasts. QPCR analysis revealed higher expression of the three major PDE4 subtypes (4a, 4b, 4d) in ADO2 osteoclasts compared in WT, consistent with reduced cAMP levels in ADO2 osteoclasts. In addition, we found that the PDE4 antagonists, rolipram and roflumilast, stimulated ADO2 and WT osteoclast formation in a dose-dependent manner. Importantly, roflumilast and rolipram displayed a concentration-dependent increase in osteoclast resorption activity which was greater in ADO2 than WT osteoclasts. Moreover, treatment with roflumilast rescued cAMP levels in ADO2 OCLs. The key findings from our studies demonstrate that osteoclasts from ADO2 mice exhibit reduced cAMP levels and PDE4 inhibition rescues cAMP levels and ADO2 osteoclast activity dysfunction in vitro. The mechanism of action of PDE4 inhibitors and their ability to reduce the high bone mass of ADO2 mice in vivo are currently under investigation. Importantly, these studies advance the understanding of the mechanisms underlying the ADO2 osteoclast dysfunction which is critical for the development of therapeutic approaches to treat clinically affected ADO2 patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Stauber T, Weinert S, Jentsch TJ (2012) Cell biology and physiology of CLC chloride channels and transporters. Compr Physiol 2:1701–1744PubMedCrossRef Stauber T, Weinert S, Jentsch TJ (2012) Cell biology and physiology of CLC chloride channels and transporters. Compr Physiol 2:1701–1744PubMedCrossRef
2.
Zurück zum Zitat Poroca DR, Pelis RM, Chappe VM (2017) ClC channels and transporters: structure, physiological functions, and implications in human chloride channelopathies. Front Pharmacol 8:151PubMedPubMedCentralCrossRef Poroca DR, Pelis RM, Chappe VM (2017) ClC channels and transporters: structure, physiological functions, and implications in human chloride channelopathies. Front Pharmacol 8:151PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Jentsch TJ, Pusch M (2018) CLC chloride channels and transporters: structure, function, physiology, and disease. Physiol Rev 98:1493–1590PubMedCrossRef Jentsch TJ, Pusch M (2018) CLC chloride channels and transporters: structure, function, physiology, and disease. Physiol Rev 98:1493–1590PubMedCrossRef
4.
Zurück zum Zitat Jentsch TJ, Stein V, Weinreich F, Zdebik AA (2002) Molecular structure and physiological function of chloride channels. Physiol Rev 82:503–568PubMedCrossRef Jentsch TJ, Stein V, Weinreich F, Zdebik AA (2002) Molecular structure and physiological function of chloride channels. Physiol Rev 82:503–568PubMedCrossRef
5.
Zurück zum Zitat Jentsch TJ, Poët M, Fuhrmann JC, Zdebik AA (2005) Physiological functions of CLC Cl- channels gleaned from human genetic disease and mouse models. Annu Rev Physiol 67:779–807PubMedCrossRef Jentsch TJ, Poët M, Fuhrmann JC, Zdebik AA (2005) Physiological functions of CLC Cl- channels gleaned from human genetic disease and mouse models. Annu Rev Physiol 67:779–807PubMedCrossRef
6.
Zurück zum Zitat Graves AR, Curran PK, Smith CL, Mindell JA (2008) The Cl-/H+ antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature 453:788–792PubMedCrossRef Graves AR, Curran PK, Smith CL, Mindell JA (2008) The Cl-/H+ antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature 453:788–792PubMedCrossRef
7.
Zurück zum Zitat Guzman RE, Grieschat M, Fahlke C, Alekov AK (2013) ClC-3 is an intracellular chloride/proton exchanger with large voltage-dependent nonlinear capacitance. ACS Chem Neurosci 4:994–1003PubMedPubMedCentralCrossRef Guzman RE, Grieschat M, Fahlke C, Alekov AK (2013) ClC-3 is an intracellular chloride/proton exchanger with large voltage-dependent nonlinear capacitance. ACS Chem Neurosci 4:994–1003PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Matsuda JJ, Filali MS, Volk KA, Collins MM, Moreland JG, Lamb FS (2008) Overexpression of CLC-3 in HEK293T cells yields novel currents that are pH dependent. Am J Physiol Cell Physiol 294:C251-262PubMedCrossRef Matsuda JJ, Filali MS, Volk KA, Collins MM, Moreland JG, Lamb FS (2008) Overexpression of CLC-3 in HEK293T cells yields novel currents that are pH dependent. Am J Physiol Cell Physiol 294:C251-262PubMedCrossRef
9.
Zurück zum Zitat Neagoe I, Stauber T, Fidzinski P, Bergsdorf EY, Jentsch TJ (2010) The late endosomal ClC-6 mediates proton/chloride countertransport in heterologous plasma membrane expression. J Biol Chem 285:21689–21697PubMedPubMedCentralCrossRef Neagoe I, Stauber T, Fidzinski P, Bergsdorf EY, Jentsch TJ (2010) The late endosomal ClC-6 mediates proton/chloride countertransport in heterologous plasma membrane expression. J Biol Chem 285:21689–21697PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Picollo A, Pusch M (2005) Chloride/proton antiporter activity of mammalian CLC proteins ClC-4 and ClC-5. Nature 436:420–423PubMedCrossRef Picollo A, Pusch M (2005) Chloride/proton antiporter activity of mammalian CLC proteins ClC-4 and ClC-5. Nature 436:420–423PubMedCrossRef
11.
Zurück zum Zitat Scheel O, Zdebik AA, Lourdel S, Jentsch TJ (2005) Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 436:424–427PubMedCrossRef Scheel O, Zdebik AA, Lourdel S, Jentsch TJ (2005) Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 436:424–427PubMedCrossRef
12.
Zurück zum Zitat Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC (2006) ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 440:220–223PubMedCrossRef Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC (2006) ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 440:220–223PubMedCrossRef
13.
Zurück zum Zitat Meadows NA, Sharma SM, Faulkner GJ, Ostrowski MC, Hume DA, Cassady AI (2007) The expression of Clcn7 and Ostm1 in osteoclasts is coregulated by microphthalmia transcription factor. J Biol Chem 282:1891–1904PubMedCrossRef Meadows NA, Sharma SM, Faulkner GJ, Ostrowski MC, Hume DA, Cassady AI (2007) The expression of Clcn7 and Ostm1 in osteoclasts is coregulated by microphthalmia transcription factor. J Biol Chem 282:1891–1904PubMedCrossRef
14.
Zurück zum Zitat Leisle L, Ludwig CF, Wagner FA, Jentsch TJ, Stauber T (2011) ClC-7 is a slowly voltage-gated 2Cl(-)/1H(+)-exchanger and requires Ostm1 for transport activity. Embo J 30:2140–2152PubMedPubMedCentralCrossRef Leisle L, Ludwig CF, Wagner FA, Jentsch TJ, Stauber T (2011) ClC-7 is a slowly voltage-gated 2Cl(-)/1H(+)-exchanger and requires Ostm1 for transport activity. Embo J 30:2140–2152PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Weinert S, Jabs S, Hohensee S, Chan WL, Kornak U, Jentsch TJ (2014) Transport activity and presence of ClC-7/Ostm1 complex account for different cellular functions. EMBO Rep 15:784–791PubMedPubMedCentralCrossRef Weinert S, Jabs S, Hohensee S, Chan WL, Kornak U, Jentsch TJ (2014) Transport activity and presence of ClC-7/Ostm1 complex account for different cellular functions. EMBO Rep 15:784–791PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Brandt S, Jentsch TJ (1995) ClC-6 and ClC-7 are two novel broadly expressed members of the CLC chloride channel family. FEBS Lett 377:15–20PubMedCrossRef Brandt S, Jentsch TJ (1995) ClC-6 and ClC-7 are two novel broadly expressed members of the CLC chloride channel family. FEBS Lett 377:15–20PubMedCrossRef
17.
Zurück zum Zitat Kornak U, Kasper D, Bösl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ (2001) Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205–215PubMedCrossRef Kornak U, Kasper D, Bösl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ (2001) Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205–215PubMedCrossRef
18.
Zurück zum Zitat Schulz P, Werner J, Stauber T, Henriksen K, Fendler K (2010) The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS ONE 5:e12585PubMedPubMedCentralCrossRef Schulz P, Werner J, Stauber T, Henriksen K, Fendler K (2010) The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS ONE 5:e12585PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Henriksen K, Gram J, Schaller S, Dahl BH, Dziegiel MH, Bollerslev J, Karsdal MA (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 164:1537–1545PubMedPubMedCentralCrossRef Henriksen K, Gram J, Schaller S, Dahl BH, Dziegiel MH, Bollerslev J, Karsdal MA (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 164:1537–1545PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Alam I, Gray AK, Chu K, Ichikawa S, Mohammad KS, Capannolo M, Capulli M, Maurizi A, Muraca M, Teti A, Econs MJ, Del Fattore A (2014) Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. Bone 59:66–75PubMedCrossRef Alam I, Gray AK, Chu K, Ichikawa S, Mohammad KS, Capannolo M, Capulli M, Maurizi A, Muraca M, Teti A, Econs MJ, Del Fattore A (2014) Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. Bone 59:66–75PubMedCrossRef
21.
Zurück zum Zitat Chu K, Snyder R, Econs MJ (2006) Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties. J Bone Miner Res 21:1089–1097PubMedCrossRef Chu K, Snyder R, Econs MJ (2006) Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties. J Bone Miner Res 21:1089–1097PubMedCrossRef
22.
Zurück zum Zitat Alam I, Gerard-O’Riley RL, Acton D, Hardman SL, Hong JM, Bruzzaniti A, Econs MJ (2021) Chloroquine increases osteoclast activity in vitro but does not improve the osteopetrotic bone phenotype of ADO2 mice. Bone 153:116160PubMedPubMedCentralCrossRef Alam I, Gerard-O’Riley RL, Acton D, Hardman SL, Hong JM, Bruzzaniti A, Econs MJ (2021) Chloroquine increases osteoclast activity in vitro but does not improve the osteopetrotic bone phenotype of ADO2 mice. Bone 153:116160PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Delaisse JM, Søe K, Andersen TL, Rojek AM, Marcussen N (2021) The mechanism switching the osteoclast from short to long duration bone resorption. Front Cell Dev Biol 9:644503PubMedPubMedCentralCrossRef Delaisse JM, Søe K, Andersen TL, Rojek AM, Marcussen N (2021) The mechanism switching the osteoclast from short to long duration bone resorption. Front Cell Dev Biol 9:644503PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat von Kleist L, Haucke V (2012) At the crossroads of chemistry and cell biology: inhibiting membrane traffic by small molecules. Traffic 13:495–504CrossRef von Kleist L, Haucke V (2012) At the crossroads of chemistry and cell biology: inhibiting membrane traffic by small molecules. Traffic 13:495–504CrossRef
25.
Zurück zum Zitat Rahman N, Ramos-Espiritu L, Milner TA, Buck J, Levin LR (2016) Soluble adenylyl cyclase is essential for proper lysosomal acidification. J Gen Physiol 148:325–339PubMedPubMedCentralCrossRef Rahman N, Ramos-Espiritu L, Milner TA, Buck J, Levin LR (2016) Soluble adenylyl cyclase is essential for proper lysosomal acidification. J Gen Physiol 148:325–339PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Tasken K, Aandahl EM (2004) Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84:137–167PubMedCrossRef Tasken K, Aandahl EM (2004) Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84:137–167PubMedCrossRef
27.
Zurück zum Zitat Taylor SS, Buechler JA, Yonemoto W (1990) cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem 59:971–1005PubMedCrossRef Taylor SS, Buechler JA, Yonemoto W (1990) cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem 59:971–1005PubMedCrossRef
28.
Zurück zum Zitat Biel M, Zong X, Ludwig A, Sautter A, Hofmann F (1999) Structure and function of cyclic nucleotide-gated channels. Rev Physiol Biochem Pharmacol 135:151–171PubMedCrossRef Biel M, Zong X, Ludwig A, Sautter A, Hofmann F (1999) Structure and function of cyclic nucleotide-gated channels. Rev Physiol Biochem Pharmacol 135:151–171PubMedCrossRef
29.
Zurück zum Zitat Finn JT, Grunwald ME, Yau KW (1996) Cyclic nucleotide-gated ion channels: an extended family with diverse functions. Annu Rev Physiol 58:395–426PubMedCrossRef Finn JT, Grunwald ME, Yau KW (1996) Cyclic nucleotide-gated ion channels: an extended family with diverse functions. Annu Rev Physiol 58:395–426PubMedCrossRef
30.
Zurück zum Zitat Bos JL (2003) Epac: a new cAMP target and new avenues in cAMP research. Nat Rev Mol Cell Biol 4:733–738PubMedCrossRef Bos JL (2003) Epac: a new cAMP target and new avenues in cAMP research. Nat Rev Mol Cell Biol 4:733–738PubMedCrossRef
31.
Zurück zum Zitat Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1–18PubMedPubMedCentralCrossRef Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1–18PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Soderling SH, Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174–179PubMedCrossRef Soderling SH, Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174–179PubMedCrossRef
33.
Zurück zum Zitat Inoue D, Watanabe R, Okazaki R (2016) COPD and osteoporosis: links, risks, and treatment challenges. Int J Chron Obstruct Pulmon Dis 11:637–648PubMedPubMedCentralCrossRef Inoue D, Watanabe R, Okazaki R (2016) COPD and osteoporosis: links, risks, and treatment challenges. Int J Chron Obstruct Pulmon Dis 11:637–648PubMedPubMedCentralCrossRef
34.
35.
Zurück zum Zitat Scuvee-Moreau J, Giesbers I, Dresse A (1987) Effect of rolipram, a phosphodiesterase inhibitor and potential antidepressant, on the firing rate of central monoaminergic neurons in the rat. Arch Int Pharmacodyn Ther 288:43–49PubMed Scuvee-Moreau J, Giesbers I, Dresse A (1987) Effect of rolipram, a phosphodiesterase inhibitor and potential antidepressant, on the firing rate of central monoaminergic neurons in the rat. Arch Int Pharmacodyn Ther 288:43–49PubMed
36.
Zurück zum Zitat Huang S, Eleniste PP, Wayakanon K, Mandela P, Eipper BA, Mains RE, Allen MR, Bruzzaniti A (2014) The Rho-GEF Kalirin regulates bone mass and the function of osteoblasts and osteoclasts. Bone 60:235–245PubMedCrossRef Huang S, Eleniste PP, Wayakanon K, Mandela P, Eipper BA, Mains RE, Allen MR, Bruzzaniti A (2014) The Rho-GEF Kalirin regulates bone mass and the function of osteoblasts and osteoclasts. Bone 60:235–245PubMedCrossRef
37.
Zurück zum Zitat Kang KS, Hong JM, Horan DJ, Lim KE, Bullock WA, Bruzzaniti A, Hann S, Warman ML, Robling AG (2019) Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism. Bone 120:166–175PubMedCrossRef Kang KS, Hong JM, Horan DJ, Lim KE, Bullock WA, Bruzzaniti A, Hann S, Warman ML, Robling AG (2019) Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism. Bone 120:166–175PubMedCrossRef
38.
Zurück zum Zitat Chen X, Zhang K, Hock J, Wang C, Yu X (2016) Enhanced but hypofunctional osteoclastogenesis in an autosomal dominant osteopetrosis type II case carrying a c.1856C>T mutation in CLCN7. Bone Res 4:16035PubMedPubMedCentralCrossRef Chen X, Zhang K, Hock J, Wang C, Yu X (2016) Enhanced but hypofunctional osteoclastogenesis in an autosomal dominant osteopetrosis type II case carrying a c.1856C>T mutation in CLCN7. Bone Res 4:16035PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vaananen HK, Halleen JM (2004) Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883–890PubMedCrossRef Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vaananen HK, Halleen JM (2004) Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883–890PubMedCrossRef
40.
Zurück zum Zitat Alam I, McQueen AK, Acton D, Reilly AM, Gerard-O’Riley RL, Oakes DK, Kasipathi C, Huffer A, Wright WB, Econs MJ (2017) Phenotypic severity of autosomal dominant osteopetrosis type II (ADO2) mice on different genetic backgrounds recapitulates the features of human disease. Bone 94:34–41PubMedCrossRef Alam I, McQueen AK, Acton D, Reilly AM, Gerard-O’Riley RL, Oakes DK, Kasipathi C, Huffer A, Wright WB, Econs MJ (2017) Phenotypic severity of autosomal dominant osteopetrosis type II (ADO2) mice on different genetic backgrounds recapitulates the features of human disease. Bone 94:34–41PubMedCrossRef
41.
Zurück zum Zitat Murrills RJ, Dempster DW (1990) The effects of stimulators of intracellular cyclic AMP on rat and chick osteoclasts in vitro: validation of a simplified light microscope assay of bone resorption. Bone 11:333–344PubMedCrossRef Murrills RJ, Dempster DW (1990) The effects of stimulators of intracellular cyclic AMP on rat and chick osteoclasts in vitro: validation of a simplified light microscope assay of bone resorption. Bone 11:333–344PubMedCrossRef
42.
Zurück zum Zitat Park YG, Kim YH, Kang SK, Kim CH (2006) cAMP-PKA signaling pathway regulates bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts. Int Immunopharmacol 6:947–956PubMedCrossRef Park YG, Kim YH, Kang SK, Kim CH (2006) cAMP-PKA signaling pathway regulates bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts. Int Immunopharmacol 6:947–956PubMedCrossRef
43.
Zurück zum Zitat Ramaswamy G, Kim H, Zhang D, Lounev V, Wu JY, Choi Y, Kaplan FS, Pignolo RJ, Shore EM (2017) Gsalpha controls cortical bone quality by regulating osteoclast differentiation via cAMP/PKA and beta-catenin pathways. Sci Rep 7:45140PubMedPubMedCentralCrossRef Ramaswamy G, Kim H, Zhang D, Lounev V, Wu JY, Choi Y, Kaplan FS, Pignolo RJ, Shore EM (2017) Gsalpha controls cortical bone quality by regulating osteoclast differentiation via cAMP/PKA and beta-catenin pathways. Sci Rep 7:45140PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat McSorley T, Stefan E, Henn V, Wiesner B, Baillie GS, Houslay MD, Rosenthal W, Klussmann E (2006) Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells. Eur J Cell Biol 85:673–678PubMedCrossRef McSorley T, Stefan E, Henn V, Wiesner B, Baillie GS, Houslay MD, Rosenthal W, Klussmann E (2006) Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells. Eur J Cell Biol 85:673–678PubMedCrossRef
45.
Zurück zum Zitat Stefan E, Wiesner B, Baillie GS, Mollajew R, Henn V, Lorenz D, Furkert J, Santamaria K, Nedvetsky P, Hundsrucker C, Beyermann M, Krause E, Pohl P, Gall I, MacIntyre AN, Bachmann S, Houslay MD, Rosenthal W, Klussmann E (2007) Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J Am Soc Nephrol 18:199–212PubMedCrossRef Stefan E, Wiesner B, Baillie GS, Mollajew R, Henn V, Lorenz D, Furkert J, Santamaria K, Nedvetsky P, Hundsrucker C, Beyermann M, Krause E, Pohl P, Gall I, MacIntyre AN, Bachmann S, Houslay MD, Rosenthal W, Klussmann E (2007) Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J Am Soc Nephrol 18:199–212PubMedCrossRef
46.
Zurück zum Zitat Takami M, Cho ES, Lee SY, Kamijo R, Yim M (2005) Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett 579:832–838PubMedCrossRef Takami M, Cho ES, Lee SY, Kamijo R, Yim M (2005) Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett 579:832–838PubMedCrossRef
47.
Zurück zum Zitat Park H, No AL, Lee JM, Chen L, Lee SY, Lee DS, Yim M (2010) PDE4 inhibitor upregulates PTH-induced osteoclast formation via CRE-mediated COX-2 expression in osteoblasts. FEBS Lett 584:173–180PubMedCrossRef Park H, No AL, Lee JM, Chen L, Lee SY, Lee DS, Yim M (2010) PDE4 inhibitor upregulates PTH-induced osteoclast formation via CRE-mediated COX-2 expression in osteoblasts. FEBS Lett 584:173–180PubMedCrossRef
48.
Zurück zum Zitat Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, Karlsson JA (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a “low-affinity” phosphodiesterase 4 conformer. Br J Pharmacol 118:649–658PubMedPubMedCentralCrossRef Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, Karlsson JA (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a “low-affinity” phosphodiesterase 4 conformer. Br J Pharmacol 118:649–658PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK (1996) Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 118:1727–1735PubMedPubMedCentralCrossRef Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK (1996) Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 118:1727–1735PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H (2010) The preclinical pharmacology of roflumilast—a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23:235–256PubMedCrossRef Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H (2010) The preclinical pharmacology of roflumilast—a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23:235–256PubMedCrossRef
51.
Zurück zum Zitat Rabe KF (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163:53–67PubMedPubMedCentralCrossRef Rabe KF (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163:53–67PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Stauber T, Wartosch L, Vishnolia S, Schulz A, Kornak U (2023) CLCN7, a gene shared by autosomal recessive and autosomal dominant osteopetrosis. Bone 168:116639PubMedCrossRef Stauber T, Wartosch L, Vishnolia S, Schulz A, Kornak U (2023) CLCN7, a gene shared by autosomal recessive and autosomal dominant osteopetrosis. Bone 168:116639PubMedCrossRef
53.
Zurück zum Zitat Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ (2003) Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 18:1513–1518PubMedCrossRef Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ (2003) Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 18:1513–1518PubMedCrossRef
54.
Zurück zum Zitat Henriksen K, Sørensen MG, Jensen VK, Dziegiel MH, Nosjean O, Karsdal MA (2008) Ion transporters involved in acidification of the resorption lacuna in osteoclasts. Calcif Tissue Int 83:230–242PubMedCrossRef Henriksen K, Sørensen MG, Jensen VK, Dziegiel MH, Nosjean O, Karsdal MA (2008) Ion transporters involved in acidification of the resorption lacuna in osteoclasts. Calcif Tissue Int 83:230–242PubMedCrossRef
55.
Zurück zum Zitat Henriksen K, Sorensen MG, Nielsen RH, Gram J, Schaller S, Dziegiel MH, Everts V, Bollerslev J, Karsdal MA (2006) Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J Bone Miner Res 21:58–66PubMedCrossRef Henriksen K, Sorensen MG, Nielsen RH, Gram J, Schaller S, Dziegiel MH, Everts V, Bollerslev J, Karsdal MA (2006) Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J Bone Miner Res 21:58–66PubMedCrossRef
57.
Zurück zum Zitat Krogstad DJ, Schlesinger PH (1987) The basis of antimalarial action: non-weak base effects of chloroquine on acid vesicle pH. Am J Trop Med Hyg 36:213–220PubMedCrossRef Krogstad DJ, Schlesinger PH (1987) The basis of antimalarial action: non-weak base effects of chloroquine on acid vesicle pH. Am J Trop Med Hyg 36:213–220PubMedCrossRef
58.
59.
Zurück zum Zitat Nicholson GC, Moseley JM, Yates AJ, Martin TJ (1987) Control of cyclic adenosine 3’,5’-monophosphate production in osteoclasts: calcitonin-induced persistent activation and homologous desensitization of adenylate cyclase. Endocrinology 120:1902–1908PubMedCrossRef Nicholson GC, Moseley JM, Yates AJ, Martin TJ (1987) Control of cyclic adenosine 3’,5’-monophosphate production in osteoclasts: calcitonin-induced persistent activation and homologous desensitization of adenylate cyclase. Endocrinology 120:1902–1908PubMedCrossRef
60.
Zurück zum Zitat Doorn J, Siddappa R, van Blitterswijk CA, de Boer J (2012) Forskolin enhances in vivo bone formation by human mesenchymal stromal cells. Tissue Eng Part A 18:558–567PubMedCrossRef Doorn J, Siddappa R, van Blitterswijk CA, de Boer J (2012) Forskolin enhances in vivo bone formation by human mesenchymal stromal cells. Tissue Eng Part A 18:558–567PubMedCrossRef
61.
Zurück zum Zitat Siddappa R, Mulder W, Steeghs I, van de Klundert C, Fernandes H, Liu J, Arends R, van Blitterswijk C, de Boer J (2009) cAMP/PKA signaling inhibits osteogenic differentiation and bone formation in rodent models. Tissue Eng Part A 15:2135–2143PubMedCrossRef Siddappa R, Mulder W, Steeghs I, van de Klundert C, Fernandes H, Liu J, Arends R, van Blitterswijk C, de Boer J (2009) cAMP/PKA signaling inhibits osteogenic differentiation and bone formation in rodent models. Tissue Eng Part A 15:2135–2143PubMedCrossRef
62.
Zurück zum Zitat Siddappa R, Doorn J, Liu J, Langerwerf E, Arends R, van Blitterswijk C, de Boer J (2010) Timing, rather than the concentration of cyclic AMP, correlates to osteogenic differentiation of human mesenchymal stem cells. J Tissue Eng Regen Med 4:356–365PubMedCrossRef Siddappa R, Doorn J, Liu J, Langerwerf E, Arends R, van Blitterswijk C, de Boer J (2010) Timing, rather than the concentration of cyclic AMP, correlates to osteogenic differentiation of human mesenchymal stem cells. J Tissue Eng Regen Med 4:356–365PubMedCrossRef
63.
Zurück zum Zitat Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, Houslay MD, Zaccolo M (2004) Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95:67–75PubMedCrossRef Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, Houslay MD, Zaccolo M (2004) Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95:67–75PubMedCrossRef
64.
Zurück zum Zitat Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, Lefkowitz RJ (2002) Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 298:834–836PubMedCrossRef Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, Lefkowitz RJ (2002) Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 298:834–836PubMedCrossRef
65.
Zurück zum Zitat Ainatzoglou A, Stamoula E, Dardalas I, Siafis S, Papazisis G (2021) The effects of PDE inhibitors on multiple sclerosis: a review of in vitro and in vivo models. Curr Pharm Des 27:2387–2397PubMedCrossRef Ainatzoglou A, Stamoula E, Dardalas I, Siafis S, Papazisis G (2021) The effects of PDE inhibitors on multiple sclerosis: a review of in vitro and in vivo models. Curr Pharm Des 27:2387–2397PubMedCrossRef
66.
Zurück zum Zitat Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297:280–290PubMed Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297:280–290PubMed
67.
Zurück zum Zitat Cho ES, Yu JH, Kim MS, Yim M (2004) Rolipram, a phosphodiesterase 4 inhibitor, stimulates osteoclast formation by inducing TRANCE expression in mouse calvarial cells. Arch Pharmacal Res 27:1258–1262CrossRef Cho ES, Yu JH, Kim MS, Yim M (2004) Rolipram, a phosphodiesterase 4 inhibitor, stimulates osteoclast formation by inducing TRANCE expression in mouse calvarial cells. Arch Pharmacal Res 27:1258–1262CrossRef
Metadaten
Titel
The PDE4 Inhibitors Roflumilast and Rolipram Rescue ADO2 Osteoclast Resorption Dysfunction
verfasst von
Jung Min Hong
Rita L. Gerard-O’Riley
Dena Acton
Imranul Alam
Michael J. Econs
Angela Bruzzaniti
Publikationsdatum
14.03.2024
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 4/2024
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-024-01191-7

Weitere Artikel der Ausgabe 4/2024

Calcified Tissue International 4/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.